IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been assigned an average rating of “Moderate Buy” from the twenty-one analysts that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $251.22.

IQV has been the subject of several analyst reports. Barclays lowered their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th.

IQVIA Stock Up 1.8 %

IQVIA stock opened at $196.54 on Thursday. The firm has a market capitalization of $34.61 billion, a P/E ratio of 26.21, a P/E/G ratio of 1.98 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The stock’s fifty day simple moving average is $199.95 and its 200-day simple moving average is $217.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts expect that IQVIA will post 10.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the 3rd quarter worth $27,000. Synergy Asset Management LLC purchased a new stake in IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC grew its position in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. GKV Capital Management Co. Inc. purchased a new position in IQVIA in the fourth quarter valued at about $39,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $44,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.